Our Pricing

Wegovy Weight Loss Injections UK: Clinical Evidence and Pricing

Published on: June 03, 2026

Searching for transparent wegovy weight loss injections uk price information? At Cured Pharmacy, Wegovy (semaglutide) starts from £79.00 with our WEIGHTLOSSNEW discount code, offering genuine UK-licensed treatment with free clinical consultation and discreet next-day delivery. Our superintendent pharmacist Tarun Kumar (GPhC 2233073) leads a UK-registered clinical team that has supported thousands of patients through evidence-based weight management programmes.

How Wegovy Semaglutide Works for Weight Loss

Wegovy contains semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist licensed by the MHRA for chronic weight management in adults with a BMI of 30 kg/m² or greater, or 27 kg/m² with at least one weight-related comorbidity [1]. Semaglutide mimics the natural GLP-1 hormone your gut produces after eating, slowing gastric emptying and signalling satiety to the brain's appetite centres.

In the landmark STEP 1 trial involving 1,961 participants, adults receiving once-weekly semaglutide 2.4mg achieved an average body weight reduction of 14.9% over 68 weeks, compared to 2.4% with placebo [1]. Importantly, 86.4% of participants on semaglutide lost at least 5% of their baseline weight — a threshold associated with meaningful improvements in cardiovascular risk markers [2].

The medication works through three complementary mechanisms: reducing appetite by acting on brain regions that regulate hunger, delaying how quickly food leaves your stomach to prolong feelings of fullness, and modulating glucose-dependent insulin secretion [3]. Unlike older appetite suppressants, semaglutide addresses the physiological drivers of weight regain that make long-term weight management challenging.

Wegovy Dosing Schedule and What to Expect

Clinical trials demonstrated that the gradual titration schedule significantly reduces the incidence of nausea and vomiting compared to starting at higher doses [3]. If you miss a dose and it's been less than five days, take it as soon as you remember. If more than five days have passed, skip that dose and resume your regular weekly schedule.

Standard Titration Protocol

Wegovy follows a carefully designed dose-escalation schedule to minimise gastrointestinal side effects whilst your body adjusts to treatment [3]. You'll begin with 0.25mg once weekly for four weeks, then increase to 0.5mg for four weeks, followed by 1mg, 1.7mg, and finally the maintenance dose of 2.4mg. Each pen delivers a single pre-set dose — you simply attach a new needle, dial, and inject subcutaneously into your abdomen, thigh, or upper arm.

Most patients notice reduced appetite within the first two weeks, though peak weight loss typically occurs between weeks 60 and 68 of continuous treatment [1]. Your UK prescriber at Cured Pharmacy will monitor your progress through follow-up consultations, adjusting the treatment plan if you experience persistent side effects or inadequate response after 12 weeks at the maintenance dose.

Wegovy Weight Loss Injections UK Price Comparison

At Cured Pharmacy, transparent upfront pricing means you'll see the exact cost before your free clinical consultation. Our WEIGHTLOSSNEW discount code reduces the starting price to £79.00, representing exceptional value compared to typical UK market rates for genuine MHRA-licensed semaglutide. All prices include your medication, clinical assessment by a UK prescriber, and discreet delivery to your door.

We guarantee the lowest prices in the UK for prescription weight loss treatments. Unlike some providers that advertise introductory rates but increase costs sharply after the first month, our pricing remains consistent throughout your treatment journey. You'll never encounter hidden consultation fees or mandatory subscription lock-ins — just honest, pharmacy-led care.

Every Wegovy pen dispensed by Cured Pharmacy comes directly from UK-licensed wholesalers, ensuring full traceability and compliance with MHRA regulations. Our GPhC registration (9012511) means we operate under the same stringent standards as high-street pharmacies, but with the convenience and cost savings of our online model.

Wegovy vs Mounjaro: Understanding Your Options

Your UK prescriber will consider factors including your baseline BMI, previous weight loss attempts, cardiovascular risk profile, and any contraindications when recommending the most suitable treatment. Both medications are prescription-only and require ongoing monitoring to ensure safe, effective use.

Mechanism and Efficacy Differences

Whilst Wegovy activates GLP-1 receptors exclusively, Mounjaro (tirzepatide) represents a newer class of dual GIP/GLP-1 receptor agonists [4]. This dual mechanism produced greater average weight loss in head-to-head comparisons — the SURPASS-2 trial showed tirzepatide 15mg achieved 12.4kg average weight reduction versus 6.2kg with semaglutide 1mg over 40 weeks [4]. However, Wegovy uses the higher 2.4mg semaglutide dose licensed specifically for weight management, which narrows this gap considerably.

Both medications require once-weekly subcutaneous injection and follow similar titration schedules to minimise side effects. The choice between them often comes down to individual response, tolerability, and prescriber assessment of your medical history. Some patients who experience inadequate weight loss on semaglutide may benefit from switching to tirzepatide, subject to clinical appropriateness [5].

Common Side Effects and How to Manage Them

The most frequently reported side effects with Wegovy are gastrointestinal: nausea (44% of participants in STEP trials), diarrhoea (30%), vomiting (24%), and constipation (24%) [1]. These effects are typically mild to moderate, occur predominantly during dose escalation, and diminish as your body adapts to treatment. Eating smaller, more frequent meals and avoiding high-fat foods can significantly reduce nausea intensity.

Serious but rare adverse events include pancreatitis, gallbladder disease, and hypoglycaemia in patients taking concomitant insulin or sulfonylureas [3]. Contact your prescriber immediately if you experience severe abdominal pain, persistent vomiting, or signs of an allergic reaction. Wegovy carries a boxed warning in the US regarding thyroid C-cell tumours observed in rodent studies, though no causal link has been established in humans — it remains contraindicated in patients with personal or family history of medullary thyroid carcinoma or Multiple Endocrine Neoplasia syndrome type 2 [3].

Our clinical team at Cured Pharmacy provides ongoing support throughout your treatment. If side effects become troublesome, your prescriber may recommend temporarily maintaining your current dose for an additional four weeks before escalating, or implementing dietary modifications to improve tolerability.

Who Can Use Wegovy Weight Loss Injections in the UK

The free online consultation at Cured Pharmacy takes under three minutes and covers your medical history, current medications, and weight management goals. Our UK-registered prescribers review every assessment individually — there are no automated approvals. If Wegovy isn't clinically appropriate for you, we'll explain why and discuss alternative evidence-based options that may better suit your circumstances.

Eligibility Criteria and Contraindications

NICE guidance recommends considering GLP-1 receptor agonists for weight management in adults with a BMI of 35 kg/m² or greater, or 30-34.9 kg/m² with significant weight-related complications such as type 2 diabetes, hypertension, or obstructive sleep apnoea [6]. Some prescribers may consider treatment at a BMI of 27 kg/m² or above in the presence of multiple comorbidities, though this falls outside standard commissioning criteria.

Wegovy is contraindicated in pregnancy, during breastfeeding, in patients under 18 years, and in those with personal or family history of medullary thyroid carcinoma or MEN 2 syndrome [3]. You should inform your prescriber if you have a history of pancreatitis, severe gastrointestinal disease, diabetic retinopathy, or renal impairment, as these conditions require careful assessment before initiating treatment.

Scientific References

1. Wilding, J. P. H., Batterham, R. L., Calanna, S., Davies, M., Van Gaal, L. F., Lingvay, I., McGowan, B. M., Rosenstock, J., Tran, M. T. D., Wadden, T. A., Wharton, S., Yokote, K., Zeuthen, N., & Kushner, R. F. (2021). Once-Weekly Semaglutide in Adults with Overweight or Obesity. New England Journal of Medicine, 384(11), 989–1002. https://doi.org/10.1056/NEJMoa2032183 [accessed 13 August 2026]
2. Davies, M., Færch, L., Jeppesen, O. K., Pakseresht, A., Pedersen, S. D., Perreault, L., Rosenstock, J., Shimomura, I., Viljoen, A., Wadden, T. A., & Lingvay, I. (2021). Semaglutide 2·4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet, 397(10278), 971–984. https://doi.org/10.1016/S0140-6736(21)00213-0 [accessed 13 August 2026]
3. Electronic Medicines Compendium. (2023). Wegovy 2.4 mg solution for injection in pre-filled pen - Summary of Product Characteristics (SmPC). https://www.medicines.org.uk/emc/product/13799/smpc [accessed 13 August 2026]
4. Jastreboff, A. M., Aronne, L. J., Ahmad, N. N., Wharton, S., Connery, L., Alves, B., Kiyosue, A., Zhang, S., Liu, B., Bunck, M. C., & Stefanski, A. (2022). Tirzepatide Once Weekly for the Treatment of Obesity. New England Journal of Medicine, 387(3), 205–216. https://doi.org/10.1056/NEJMoa2206038 [accessed 13 August 2026]
5. Frías, J. P., Davies, M. J., Rosenstock, J., Pérez Manghi, F. C., Fernández Landó, L., Bergman, B. K., Liu, B., Cui, X., Brown, K. D., & SURPASS-2 Investigators. (2021). Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes. New England Journal of Medicine, 385(6), 503–515. https://doi.org/10.1056/NEJMoa2107519 [accessed 13 August 2026]
6. National Institute for Health and Care Excellence. (2023). Semaglutide for managing overweight and obesity. Technology appraisal guidance [TA875]. https://www.nice.org.uk/guidance/ta875 [accessed 13 August 2026]
7. Pi-Sunyer, X., Astrup, A., Fujioka, K., Greenway, F., Halpern, A., Krempf, M., Lau, D. C., le Roux, C. W., Violante Ortiz, R., Jensen, C. B., Wilding, J. P., & NN8022-1807 Study Group. (2015). A Randomized, Controlled Trial of 3.0 mg of Liraglutide in Weight Management. New England Journal of Medicine, 373(1), 11–22. https://doi.org/10.1056/NEJMoa1411892 [accessed 13 August 2026]
8. NHS. (2026). Tirzepatide: a medicine to manage type 2 diabetes and treat obesity. https://www.nhs.uk/medicines/tirzepatide/ Accessed 13 August 2026.
9. NHS. (2026). Overweight and obesity in adults. https://www.nhs.uk/conditions/overweight-and-obesity/ Accessed 13 August 2026.
10. NHS England. (2026). Weight management injections. https://www.england.nhs.uk/ourwork/prevention/obesity/medicines-for-obesity/weight-management-injections/ Accessed 13 August 2026.

Information on this page is for educational purposes only and is not medical advice. All prescription treatments require clinical assessment by a UK-registered prescriber. Always consult a qualified healthcare professional before starting any new medication. Individual results may vary, and weight loss outcomes depend on adherence to treatment alongside dietary and lifestyle modifications.